Business Context and Reporting Period
This Form 8-K Current Report was filed by PharmAthene, Inc. on October 29, 2010. The filing primarily addresses a material definitive agreement regarding a public equity offering, the early conversion of senior convertible notes by affiliated holders, and significant updates regarding the company's regulatory status, litigation, and government contract programs.
Key Financial Metrics and Capital Structure
- Equity Offering: The Company entered into an underwriting agreement to sell 4,300,000 shares of common stock at $3.50 per share.
- Net Proceeds: Expected net proceeds are approximately $14.1 million before offering expenses.
- Over-Allotment: The underwriter was granted an option to acquire an additional 645,000 shares to cover overallotments.
- Convertible Debt: Approximately $19.3 million in aggregate principal amount of 10% senior convertible notes remains outstanding. These notes are convertible into up to approximately 8.5 million shares of common stock.
- Use of Proceeds: Funds will be used to repay certain indebtedness (specifically related to the early conversion of notes) and for general corporate purposes.
Material Changes and Corporate Actions
- Early Note Conversion: On October 29, 2010, eight note holders (including five affiliated funds and affiliates/officers/directors) elected to convert their 10% senior convertible notes prior to their July 2011 maturity. In addition to receiving shares, these holders received cash payments for interest foregone between the conversion date and the maturity date.
- Related Party Transactions: MPM Bioventures is purchasing 430,000 shares in the offering under the same terms as the public. Certain affiliates, officers, and directors are receiving cash payments from the offering proceeds related to their note conversions.
- Listing Status: The Company is subject to conditional listing on the NYSE Amex due to non-compliance with stockholders' equity and net loss standards. A compliance plan was submitted to regain compliance by January 26, 2012.
Outlook, Risks, and Management Commentary
Regulatory and Litigation Risks
- SIGA Litigation: A motion for summary judgment filed by SIGA Technologies, Inc. is pending. A decision was expected by the end of October 2010. A ruling in favor of SIGA could dismiss significant claims, limiting the Company's chances for a remedy.
- Delisting Risk: If the Company fails to meet continued listing standards by January 26, 2012, or fails to show progress on its compliance plan, the NYSE Amex could initiate delisting proceedings.
Program Updates
- Protexia (Nerve Agent Countermeasure): The U.S. Department of Defense (DoD) has deferred a decision on funding advanced development due to budget constraints and concerns regarding the duration of protection. The current contract for milk collection ends December 31, 2010, and will not be extended. The Company plans to eliminate transgenic goat operations and may incur wind-down costs and potential asset write-downs in Q4 2010.
- Advanced Expression System (AES): The Company is pursuing a second-generation, cell-based approach for rBChE production. Discussions are advanced for a new DoD contract of up to $5.9 million for initial work, with a potential award before the end of 2010. A white paper for up to $30 million over three years was submitted in September 2010.
- Valortim: Following a partial clinical hold, skin testing suggested adverse reactions were not allergic. The FDA and Safety Monitoring Committee agreed to a plan for an IV dose-escalation study with a slower infusion rate. Dosing of the first subject is scheduled for January 2011. The Company plans to submit a white paper to BARDA for advanced development funding exceeding $100 million before the end of 2010.
- SparVax: The Company has implemented organizational changes following a BARDA performance evaluation and anticipates a positive interim assessment before year-end.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds of the $14.1 million equity offering.
- Monitor the court's decision on the SIGA Technologies summary judgment motion.
- Confirm the award and terms of the anticipated $5.9 million DoD contract for the AES program.
- Track the Company's progress on the NYSE Amex compliance plan to avoid delisting by January 2012.
- Review Q4 2010 financial statements for specific severance costs and potential asset write-downs related to the termination of Protexia operations.
- Confirm FDA approval to proceed with the Valortim IV dose-escalation study in January 2011.